Press release
Investigation announced for Investors who lost money with shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
An investigation for investors in AN2 Therapeutics, Inc. (NASDAQ: ANTX) shares over potential securities laws violations.
Investors who purchased shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AN2 Therapeutics, Inc. (NASDAQ: ANTX) concerning whether a series of statements by AN2 Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Menlo Park, CA based AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
On February 12, 2024, AN2 Therapeutics, Inc. announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
Shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX) declined from $21.40 per share on February 06, 2024, to as low as $3.21 per share on February 21, 2024.
Those who purchased shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX) here
News-ID: 3394468 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for AN2
Nontuberculous Mycobacterial Infections Market Analysis: Epidemiology, Therapies …
The total Nontuberculous Mycobacterial Treatment Market was approximately USD 360 million in the US in 2023. the majority of the Nontuberculous Mycobacterial Infections Market Share was of ARIKAYCE, with a revenue of approximately USD 223 million for refractory MAC. This figure is projected to grow further by 2034, driven by continued advancements in Nontuberculous Mycobacterial Infections treatment and increasing awareness.
The Nontuberculous Mycobacterial (NTM) Infections market is expected to grow in…
Non Tuberculous Mycobacterial Infections Market Dynamics Indicate Upward Traject …
The Key Non- Tuberculous Mycobacterial Infections Companies in the market include - Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others .
The Non- Tuberculous Mycobacterial Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non- Tuberculous Mycobacterial Infections pipeline products will significantly revolutionize the Non- Tuberculous Mycobacterial Infections market…
Nontuberculous Mycobacterial Infection Market Outlook 2034 - Clinical Trials, Ma …
Nontuberculous Mycobacterial Infections Market Size in the US was approximately USD 360 million in 2023 and is projected to increase during the forecast period (2024-2034).
Nontuberculous Mycobacterial Market Summary
The Nontuberculous Mycobacterial (NTM) infections market is expected to grow steadily from 2024 to 2034, driven by improved diagnostics, new therapies, and greater disease awareness. Aging populations, who are more susceptible to NTM infections, contribute to rising diagnosed cases. Current treatments rely on…
Nontuberculous Mycobacterial Infections Market: Epidemiology, Therapies, Compani …
Nontuberculous Mycobacterial Infections therapies, such as ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, MNKD-101 (Clofazimine Inhalation Suspension), SPR720 (Fobrepodacin), and others, are expected to boost the Nontuberculous Mycobacterial Infections Market in the upcoming years.
DelveInsight has launched a new report on "Nontuberculous Mycobacterial Infections - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Nontuberculous Mycobacterial Infections, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial Infections…
Nontuberculous Mycobacterial Infections Treatment Market Size in the 7MM is expe …
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.
Discover Key Insights into the Nontuberculous Mycobacterial Market with DelveInsight's In-Depth Report @ Nontuberculous Mycobacterial Market Size- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Nontuberculous Mycobacterial Market Report
• According to DelveInsight's epidemiology model, the total Nontuberculous…
MAC Lung Disease Market Statistics Expected to Experience Major Growth by 2034, …
DelveInsight's "MAC Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the MAC Lung Disease, historical and forecasted epidemiology as well as the MAC Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of MAC Lung Disease, offering comprehensive insights into the MAC Lung Disease revenue trends,…
